Additionally, this process can be complicated by genetic variations (e.g., CYP2C19 and CYP3A4) alternating the metabolism of SSRIs and comorbid psychiatric disorders contributing to sexual dysfunction [17–23]. Here, CYP3A4 is linked to psychiatric disorder.